Precision medicine has transformed drug development and commercial strategy across oncology, rare disease, immunology, and neuroscience. A drug approved with a companion diagnostic for a biomarker-defined patient population achieves regulatory approval faster, commands premium pricing, and builds a defensible commercial position. Tagrisso for EGFR-mutant lung cancer generates revenues of approximately $3 billion annually from a patient population defined by a single molecular test. Roche’s integrated pharmaceutical-diagnostics model remains the industry benchmark.
Topics Covered
• Companion Diagnostic Co-Development Strategy
• Oncology Precision Medicine
• Neurological Precision Medicine
• Rare Disease Precision Medicine
• Immunology Precision Medicine
• Market Access and Precision Medicine
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. Companion Diagnostic Co-Development Strategy
4. Oncology Precision Medicine
5. Neurological Precision Medicine
6. Rare Disease Precision Medicine
7. Immunology Precision Medicine
8. Market Access and Precision Medicine
9. Strategic Conclusions and Recommendations
10. Appendix
List of Tables
Table 1. Technology Maturity Assessment 2025
Table 2. Companion Diagnostic Co-Development Strategy
Table 3. Oncology Precision Medicine
Table 4. Neurological Precision Medicine
Table 5. Rare Disease Precision Medicine
Table 6. Immunology Precision Medicine
Table 7. Market Access and Precision Medicine
Table 8. Leading Companies — Technology Investment and Strategy 2025
Table 9. M&A and Partnership Activity 2023-2025
Table 10. Key Risks and Mitigation Strategies
Companies Profiled
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Pfizer
Novartis
Johnson & Johnson
Daiichi Sankyo
Seagen
AbbVie
